These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29741285)

  • 21. Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis.
    Liang X; Fan R; Sun J; Shaikh J; Taneja A; Gupta S; Hamed K
    Adv Ther; 2016 Apr; 33(4):519-31. PubMed ID: 26921204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genotyping of immune-related loci associated with delayed HBeAg seroconversion in immune-active chronic hepatitis B patients.
    Liu WC; Wu IC; Chiu YC; Tseng KC; Chen CY; Chiu HC; Cheng PN; Chang TT
    Antiviral Res; 2020 Apr; 176():104719. PubMed ID: 32004619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection.
    Liaw YF; Lau GK; Kao JH; Gane E
    Dig Dis Sci; 2010 Oct; 55(10):2727-34. PubMed ID: 20238245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis B e antigen and the risk of hepatocellular carcinoma.
    Yang HI; Lu SN; Liaw YF; You SL; Sun CA; Wang LY; Hsiao CK; Chen PJ; Chen DS; Chen CJ;
    N Engl J Med; 2002 Jul; 347(3):168-74. PubMed ID: 12124405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B.
    Lee HW; Chon YE; Kim BK; Yip TC; Tse YK; Wong GL; Wong VW; Chan HL; Ahn SH
    Eur J Intern Med; 2021 Feb; 84():68-73. PubMed ID: 33288393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up of children with postnatal immunoprophylaxis failure who were infected with hepatitis B virus surface antigen gene mutant.
    Hsu HY; Chang MH; Ni YH; Jeng YM; Chiang CL; Chen HL; Wu JF; Chen PJ
    J Infect Dis; 2013 Apr; 207(7):1047-57. PubMed ID: 23300165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion.
    Yang HC; Chen CL; Shen YC; Peng CY; Liu CJ; Tseng TC; Su TH; Chuang WL; Yu ML; Dai CY; Liu CH; Chen PJ; Chen DS; Kao JH
    Hepatology; 2013 Mar; 57(3):934-43. PubMed ID: 23112104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.
    Qiu YW; Huang LH; Yang WL; Wang Z; Zhang B; Li YG; Su TT; Zhou HY; Xu W; Wang XD; Dai YP; Gan JH
    Int J Infect Dis; 2016 Feb; 43():43-48. PubMed ID: 26523639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural regression of fibrosis in chronic hepatitis B.
    Ohkoshi S; Hirono H; Watanabe K; Hasegawa K; Kamimura K; Yano M
    World J Gastroenterol; 2016 Jun; 22(24):5459-66. PubMed ID: 27350724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
    Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
    J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B.
    Kim HS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    Gastroenterology; 2009 Feb; 136(2):505-12. PubMed ID: 19101558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High Prevalence of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Infection in Thailand.
    Wanich N; Vilaichone RK; Chotivitayatarakorn P; Siramolpiwat S
    Asian Pac J Cancer Prev; 2016; 17(6):2857-60. PubMed ID: 27356702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
    Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
    J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
    Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
    Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction of chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low risk patients.
    Lin D; Yang HI; Nguyen N; Hoang J; Kim Y; Vu V; Le A; Chaung K; Nguyen V; Trinh H; Li J; Zhang J; Hsing A; Chen CJ; Nguyen MH
    Aliment Pharmacol Ther; 2016 Oct; 44(8):846-55. PubMed ID: 27549411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients With Indeterminate Phase.
    Tseng TC; Hosaka T; Liu CJ; Suzuki F; Hong CM; Kumada H; Yang WT; Hsu CY; Su TH; Yang HC; Liu CH; Chen PJ; Chen HH; Kao JH
    Am J Gastroenterol; 2022 May; 117(5):748-757. PubMed ID: 35191399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis.
    Chien J; Liu J; Lee MH; Jen CL; Batrla-Utermann R; Lu SN; Wang LY; You SL; Yang HI; Chen CJ
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1971-1977. PubMed ID: 27118149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion.
    Lau GK
    Liver Int; 2010 Apr; 30(4):512-20. PubMed ID: 20102511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.